Cargando…

Informing iQOS Regulations in the United States: A Synthesis of What We Know

The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International’s (PMI) “iQOS” has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Berg, Carla J., Bar-Zeev, Yael, Levine, Hagai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384757/
https://www.ncbi.nlm.nih.gov/pubmed/32719733
http://dx.doi.org/10.1177/2158244019898823
_version_ 1783563661008175104
author Berg, Carla J.
Bar-Zeev, Yael
Levine, Hagai
author_facet Berg, Carla J.
Bar-Zeev, Yael
Levine, Hagai
author_sort Berg, Carla J.
collection PubMed
description The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International’s (PMI) “iQOS” has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Administration announced permission for PMI to sell iQOS in the United States in April 2019, and iQOS was launched in October 2019. Decisions pending its modified risk tobacco product (MRTP) application will occur subsequently. The U.S. regulatory efforts regarding iQOS could be informed by examining (a) Philip Morris USA other product marketing efforts and (b) the iQOS market in countries where it is available. This article briefly addresses these two points with extant literature and suggests that future research should address important gaps in what is currently known, including strategic international collaborations and research, which historically has been critical for advancing tobacco control globally.
format Online
Article
Text
id pubmed-7384757
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-73847572020-07-27 Informing iQOS Regulations in the United States: A Synthesis of What We Know Berg, Carla J. Bar-Zeev, Yael Levine, Hagai Sage Open Article The tobacco industry offers various products, including heated tobacco products (HTPs). Philip Morris International’s (PMI) “iQOS” has the greatest HTP market share, as well as research on its use and impact. iQOS was released in 2014 and is now in more than 40 countries. The U.S. Food and Drug Administration announced permission for PMI to sell iQOS in the United States in April 2019, and iQOS was launched in October 2019. Decisions pending its modified risk tobacco product (MRTP) application will occur subsequently. The U.S. regulatory efforts regarding iQOS could be informed by examining (a) Philip Morris USA other product marketing efforts and (b) the iQOS market in countries where it is available. This article briefly addresses these two points with extant literature and suggests that future research should address important gaps in what is currently known, including strategic international collaborations and research, which historically has been critical for advancing tobacco control globally. 2020-01-09 2020 /pmc/articles/PMC7384757/ /pubmed/32719733 http://dx.doi.org/10.1177/2158244019898823 Text en Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Berg, Carla J.
Bar-Zeev, Yael
Levine, Hagai
Informing iQOS Regulations in the United States: A Synthesis of What We Know
title Informing iQOS Regulations in the United States: A Synthesis of What We Know
title_full Informing iQOS Regulations in the United States: A Synthesis of What We Know
title_fullStr Informing iQOS Regulations in the United States: A Synthesis of What We Know
title_full_unstemmed Informing iQOS Regulations in the United States: A Synthesis of What We Know
title_short Informing iQOS Regulations in the United States: A Synthesis of What We Know
title_sort informing iqos regulations in the united states: a synthesis of what we know
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384757/
https://www.ncbi.nlm.nih.gov/pubmed/32719733
http://dx.doi.org/10.1177/2158244019898823
work_keys_str_mv AT bergcarlaj informingiqosregulationsintheunitedstatesasynthesisofwhatweknow
AT barzeevyael informingiqosregulationsintheunitedstatesasynthesisofwhatweknow
AT levinehagai informingiqosregulationsintheunitedstatesasynthesisofwhatweknow